Predictive Biomarkers for Response to Nivolumab in Head and Neck Squamous Cell Carcinoma

Conditions:   HNSCC;   DNA Damage;   DNA Double Strand Break
Interventions:   Other: Biomarker Research;   Drug: Nivolumab
Sponsor:   Attikon Hospital
Recruiting

https://ift.tt/2MFjPxJ